| Literature DB >> 32824627 |
Berta Alcover-Sanchez1, Gonzalo Garcia-Martin1, Francisco Wandosell1, Beatriz Cubelos1.
Abstract
Myelination is required for fast and efficient synaptic transmission in vertebrates. In the central nervous system, oligodendrocytes are responsible for creating myelin sheaths that isolate and protect axons, even throughout adulthood. However, when myelin is lost, the failure of remyelination mechanisms can cause neurodegenerative myelin-associated pathologies. From oligodendrocyte progenitor cells to mature myelinating oligodendrocytes, myelination is a highly complex process that involves many elements of cellular signaling, yet many of the mechanisms that coordinate it, remain unknown. In this review, we will focus on the three major pathways involved in myelination (PI3K/Akt/mTOR, ERK1/2-MAPK, and Wnt/β-catenin) and recent advances describing the crosstalk elements which help to regulate them. In addition, we will review the tight relation between Ras GTPases and myelination processes and discuss its potential as novel elements of crosstalk between the pathways. A better understanding of the crosstalk elements orchestrating myelination mechanisms is essential to identify new potential targets to mitigate neurodegeneration.Entities:
Keywords: ERK1/2-MAPK; PI3K/Akt/mTOR; R-Ras; Wnt/β-catenin; myelin; neurodegeneration; oligodendrocyte
Mesh:
Substances:
Year: 2020 PMID: 32824627 PMCID: PMC7460555 DOI: 10.3390/ijms21165911
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Schematic representation of PI3K/Akt/mTOR, ERK1/2-MAPK, and Wnt/β-catenin pathways. (a) PI3K/Akt/mTOR signaling pathway key elements for oligodendrocyte maturation and myelination. Arrowheads imply positive interactions while bars indicate inhibitory signals. BDNF: brain-derived neurotrophic factor, NGF: nerve growth factor, NT3: neurotrophin 3, (s)Nrg1-III: (soluble) Neuregulin 1 type III, BACE1: β-site amyloid precursor protein cleaving enzyme 1, RTKs: receptors tyrosine kinase, IRS-1: insulin receptor substrate 1, PI3K: phosphoinositide-3 kinase, PIP2: phosphatidylinositol (4,5)-biphosphate, PIP3: phosphatidylinositol (3,4,5)-triphosphate, PTEN: phosphatase and tensin homolog, PDK-1: 3-phosphoinositide-dependent protein kinase 1, Akt: protein kinase B, TSC1/2: tuberous sclerosis complex, Rheb: Ras homolog enriched in brain, mTOR: mammalian target of rapamycin, mLST8: target of rapamycin complex subunit LST8, Raptor: regulatory associated protein of mTOR, Rictor: rapamycin-insensitive companion of mTOR, SIN1: Target of rapamycin complex 2 subunit MAPKAP1, p70S6K: Ribosomal protein S6 kinase beta-1, S6RP: Ribosomal protein S6, SREBPs: Sterol regulatory element-binding proteins. (b) ERK1/2-MAPK signaling pathway crucial elements for oligodendrocyte maturation and myelination. Arrowheads imply positive interactions while bars indicate inhibitory signals. PDGF: platelet-derived growth factor, FGF-2: fibroblast growth factor 2, RTKs: receptors tyrosine kinase, IRS-1: insulin receptor substrate 1, Grb2: growth factor receptor-bound protein 2, Sos: son of sevenless, MEK1/2: mitogen-activated protein kinase, ERK1/2: extracellular signal-regulated kinases 1 and 2, p70S6K: Ribosomal protein S6 kinase beta-1, p90RSK: p90 ribosomal S6 kinase, S6RP: Ribosomal protein S6, MyRF: Myelin regulatory factor. (c) Wnt/β-catenin signaling pathway essential elements for oligodendrocyte maturation and myelination. Arrowheads imply positive interactions. Lrp5/6: Lipoprotein receptor-related proteins 5/6, Dvl: disheveled, GSK3: glycogen synthase kinase 3, CK1: casein kinase 1, APC: adenomatous polyposis coli, βcat: β-catenin, TCF4 (TCF2l7): transcription factor 4.
Studies supporting the relevance of the PI3K/Akt/mTOR signaling pathway in OL development.
| Experimental | Myelin Thickness | Myelination Degree | Phosphorylation of Downstream Elements | Myelin Proteins Expression | Nº of Mature OLs | Nº of OPCs | OL Differentiation | References |
|---|---|---|---|---|---|---|---|---|
|
| - | Normal | - | - | Normal | Normal | Normal | [ |
|
| + | + | + | + | Normal | Normal | Enhanced | [ |
| Rapamycin 2 | - | - | - | - | [ | |||
|
| + | + | Normal | Normal | [ | |||
|
| + | + | + | Normal | Normal | Normal | [ | |
|
| - | - | - | - | - | + | Delayed | [ |
|
| Normal | Slightly - | - | Normal | - | Increased | [ | |
|
| - | - | - | - | Normal | Normal | [ | |
|
| - | Delayed myelination | Normal | Normal | Normal | Normal | [ | |
|
| - | - | - | - | - | + | Delayed | [ |
|
| - | + | - | [ | ||||
|
| Normal | - | - | - | - | + | Impaired | [ |
|
| + (later is normal) | Enhanced remyelination | + | Normal | Normal | Normal | [ | |
|
| - (later is normal) | Delayed remyelination | Normal | Normal | [ |
(-) indicates lower levels or numbers, (+) indicates higher levels or numbers. 1 constitutively active Akt, 2 mTOR inhibitor.
Studies supporting the relevance of the ERK1/2-MAPK signaling pathway in OL development.
| Experimental | Myelin Thickness | Myelination Degree/Start of Myelination | Phosphorylation of Downstream Elements | Myelin Proteins Expression | Cellular Proliferation | Nº of Mature OLs | Nº of OPCs | OL Differentiation | References |
|---|---|---|---|---|---|---|---|---|---|
|
| - | -/Delayed | - | + | Normal | + | Normal | [ | |
|
| - | -/Delayed | - | - | Normal | Normal | Normal | Normal | [ |
|
| - | Normal/Normal | - | Normal | Normal | Normal | [ | ||
|
| Slightly -/Delayed | Normal | - | Normal | Delayed | [ | |||
|
| + | Normal/Enhanced remyelination | + | + | Normal | Normal | Normal | Normal | [ |
|
| + | +/Normal | + | + | Normal | + | [ | ||
|
| - | - | - | [ |
(-) indicates lower levels or numbers, (+) indicates higher levels or numbers. (1) constitutively active MEK1.
Studies supporting the relevance of the Wnt/β-catenin signaling pathway in OL development.
| Experimental | Myelination Degree | Myelin Proteins Expression | Cellular Proliferation | Nº of Mature OLs | Nº of Immature OLs (OPCs) | OL Differentiation | References |
|---|---|---|---|---|---|---|---|
|
| - | - | - | - | - | Impaired | [ |
|
| Delayed remyelination | Normal | - | Normal | Delayed | [ | |
| Treatment with XAV939 1 | + | + | Normal | + | - | Enhanced | [ |
| GSK-3Β inhibitors | + | + | + | + | + | Normal | [ |
|
| - | PLP+ decreased | - | Normal | Delayed | [ | |
|
| - | - | Normal | - | Normal | Delayed | [ |
|
| - | - | - | Delayed | [ |
(-) indicates lower levels or numbers, (+) indicates higher levels or numbers. 1 XAV939 stabilizes Axin2, 2 constitutively active β-Catenin.
Figure 2Schematic representation of PI3K/Akt/mTOR, ERK1/2-MAPK, and Wnt/β-catenin pathways and their crosstalk elements. PI3K/Akt/mTOR (blue, left), ERK1/2-MAPK (magenta, middle) and Wnt/β-catenin (green, right). Crosstalk elements between two or more pathways are highlighted in yellow. Arrowheads imply positive interactions while bars indicate inhibitory signals. CDK5: cyclin-dependent kinase 5.
Figure 3R-Ras molecular structure and domains. (a) Representation of the R-Ras primary structure showing domains related to its function. Switch I and II (blue and red) are critical interfaces for downstream effectors and part of the nucleotide-binding pocket. The phosphate-binding loop (P-loop, orange) and the N/TKxD (green) regions are important for binding nucleotides, while the DxxG (violet) motif confers specificity for guanosine nucleotides. The CaaX C-terminal region is crucial for membrane attachment via prenylation or fatty acid modification. (b) Crystal structure of R-Ras1 bound to GDP (PDB: 2FN4) with highlighted regions corresponding to the ones in (a). GDP is shown as a ball and stick model, with each atom colored by element. The lower box represents the molecular surface model showing how GDP accommodates within the hydrophobic region. (c) The C-terminal ends of R-Ras1, R-Ras2, and R-Ras3, which constitute the “hypervariable region” (HVR), show significant sequence diversity important for their subcellular localization. CaaX box is underlined in yellow, with “C” being a cysteine substrate for prenylation, “a” any aliphatic amino acid, and “X” any amino acid.